82_FR_11398 82 FR 11364 - Government-Owned Inventions; Availability for Licensing

82 FR 11364 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 34 (February 22, 2017)

Page Range11364-11364
FR Document2017-03451

The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

Federal Register, Volume 82 Issue 34 (Wednesday, February 22, 2017) 
[Federal Register Volume 82, Number 34 (Wednesday, February 22, 2017)]
[Notices]
[Page 11364]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-03451]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the patent applications listed below may be obtained by communicating 
with the indicated licensing contact at the Technology Transfer and 
Intellectual Property Office, National Institute of Allergy and 
Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required 
to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology descriptions follow.
    Inhibition of host heme oxygenase-1 as an adjunctive treatment to 
improve the outcome of conventional antibiotic chemotherapy of 
Mycobacterium tuberculosis (Mtb) infection.

Description of Technology

    This invention describes the adjunctive use of heme oxygenase-1 
(HO-1) inhibitors to improve the outcome of conventional antibiotic 
treatment for tuberculosis. The existent standard of care requires 
prolonged administration of drug. Due to the long duration of 
treatment, methods that can more rapidly control tuberculosis in 
patients are clearly needed.
    NIAID researchers have discovered that inhibition of host HO-1 
reduces Mycobacterium tuberculosis (Mtb) growth in vivo and, more 
importantly, when used as an adjunct to conventional chemotherapy, 
results in a marked improvement in pulmonary bacterial control. In 
particular, it was found using a mouse model that HO-1 inhibitors 
enhance bacterial clearance when used in conjunction with conventional 
antibiotic therapy. Further, no obvious toxic side effects were found. 
Since this host-directed strategy does not directly target the pathogen 
itself, it may have an added advantage as a treatment for infections 
with antibiotic-resistant Mtb strains.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.
    Potential Commercial Applications:
     Therapeutic for Mtb.
    Competitive Advantages:
     Innovative, more rapidly effective therapeutics for 
tuberculosis are sorely needed due to the continued importance of TB as 
a global infectious disease and the increasing emergence of multi-drug 
resistant strains.
     This invention is a host-directed therapy.
    Development Stage: Pre-Clinical.
    Inventors:

F. Alan Sher, NIAID, NIH
Diego L. Costa, NIAID, NIH
Bruno B. Andrade, NIAID, NIH

    Publications: Costa, Diego L., et al. ``Pharmacological Inhibition 
of Host Heme Oxygenase-1 Suppresses Mycobacterium tuberculosis 
Infection In Vivo by a Mechanism Dependent on T Lymphocytes.'' mBio 7.5 
(2016): e01675-16.
    Intellectual Property: HHS Reference No. E-174-2016/0--U.S. Patent 
Application No. 62/357,558, filed 07/01/2016.
    Licensing Contact: James M. Robinson; [email protected]; 301-
761-7542.
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
evaluate HO-1 inhibitors in treating human tuberculosis. For 
collaboration opportunities, please contact James M. Robinson; 
[email protected]; 301-761-7542.

    Dated: February 16, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-03451 Filed 2-21-17; 8:45 am]
 BILLING CODE 4140-01-P

11364 Federal Register / Vol. 82, No. 34 / Wednesday, February 22, 2017 / Notices Time: 10:30 a.m. to 11:45 a.m. (HO–1) inhibitors to improve the treating human tuberculosis. For Agenda: To review and evaluate grant outcome of conventional antibiotic collaboration opportunities, please applications. treatment for tuberculosis. The existent contact James M. Robinson; Place: National Institute on Aging, Gateway Building, Suite 2W200, 7201 standard of care requires prolonged James.Robinson4@nih.gov; 301–761– Wisconsin Avenue, Bethesda, MD 20892, administration of drug. Due to the long 7542. (Telephone Conference Call). duration of treatment, methods that can Dated: February 16, 2017. Contact Person: Ramesh Vemuri, Ph.D., more rapidly control tuberculosis in Suzanne Frisbie, Chief, Scientific Review Branch, Scientific patients are clearly needed. Deputy Director, Technology Transfer and Review Branch, National Institute on Aging, NIAID researchers have discovered National Institutes of Health, 7201 Wisconsin Intellectual Property Office, National Institute that inhibition of host HO–1 reduces of Allergy and Infectious Diseases. Avenue, Suite 2C–212, Bethesda, MD 20892, Mycobacterium tuberculosis (Mtb) 301–402–7700, rv23r@nih.gov. [FR Doc. 2017–03451 Filed 2–21–17; 8:45 am] growth in vivo and, more importantly, (Catalogue of Federal Domestic Assistance BILLING CODE 4140–01–P Program Nos. 93.866, Aging Research, when used as an adjunct to National Institutes of Health, HHS) conventional chemotherapy, results in a marked improvement in pulmonary DEPARTMENT OF HEALTH AND Dated: February 16, 2017. bacterial control. In particular, it was Melanie J. Pantoja, HUMAN SERVICES found using a mouse model that HO–1 Program Analyst, Office of Federal Advisory inhibitors enhance bacterial clearance National Institutes of Health Committee Policy. when used in conjunction with [FR Doc. 2017–03446 Filed 2–21–17; 8:45 am] conventional antibiotic therapy. National Cancer Institute; Notice of BILLING CODE 4140–01–P Further, no obvious toxic side effects Closed Meetings were found. Since this host-directed Pursuant to section 10(d) of the strategy does not directly target the Federal Advisory Committee Act, as DEPARTMENT OF HEALTH AND pathogen itself, it may have an added HUMAN SERVICES amended (5 U.S.C. App.), notice is advantage as a treatment for infections hereby given of the following meetings. National Institutes of Health with antibiotic-resistant Mtb strains. The meetings will be closed to the This technology is available for public in accordance with the Government-Owned Inventions; licensing for commercial development provisions set forth in sections Availability for Licensing in accordance with 35 U.S.C. 209 and 37 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., CFR part 404, as well as for further as amended. The grant applications and AGENCY: National Institutes of Health, development and evaluation under a HHS. the discussions could disclose research collaboration. confidential trade secrets or commercial ACTION: Notice. Potential Commercial Applications: property such as patentable material, • Therapeutic for Mtb. and personal information concerning SUMMARY: The inventions listed below Competitive Advantages: individuals associated with the grant are owned by an agency of the U.S. • Innovative, more rapidly effective applications, the disclosure of which Government and are available for therapeutics for tuberculosis are sorely would constitute a clearly unwarranted licensing to achieve expeditious needed due to the continued importance invasion of personal privacy. commercialization of results of of TB as a global infectious disease and federally-funded research and Name of Committee: National Cancer the increasing emergence of multi-drug development. Foreign patent Institute Special Emphasis Panel; resistant strains. applications are filed on selected Radiotherapy in Combination with Systemic • This invention is a host-directed Agents. inventions to extend market coverage for companies and may also be available therapy. Date: March 20, 2017. for licensing. Development Stage: Pre-Clinical. Time: 12:00 p.m. to 5:00 p.m. Inventors: Agenda: To review and evaluate grant FOR FURTHER INFORMATION CONTACT: applications. Licensing information and copies of the F. Alan Sher, NIAID, NIH Place: National Cancer Institute Shady patent applications listed below may be Diego L. Costa, NIAID, NIH Grove, 9609 Medical Center Drive, Room obtained by communicating with the Bruno B. Andrade, NIAID, NIH 7W234, Rockville, MD 20850 (Telephone indicated licensing contact at the Publications: Costa, Diego L., et al. Conference Call). Technology Transfer and Intellectual ‘‘Pharmacological Inhibition of Host Contact Person: Adriana Stoica, Ph.D., Property Office, National Institute of Heme Oxygenase-1 Suppresses Scientific Review Officer, Resources and Allergy and Infectious Diseases, 5601 Mycobacterium tuberculosis Infection In Training Review Branch, Division of Vivo by a Mechanism Dependent on T Extramural Activities, National Cancer Fishers Lane, Rockville, MD 20852; tel. Institute, NIH, 9609 Medical Center Drive, 301–496–2644. A signed Confidential Lymphocytes.’’ mBio 7.5 (2016): Room 7W234, Bethesda, MD 20892–9750, Disclosure Agreement will be required e01675–16. 240–276–6368, Stoicaa2@mail.nih.gov. to receive copies of unpublished patent Intellectual Property: HHS Reference Name of Committee: National Cancer applications. No. E–174–2016/0—U.S. Patent Institute Special Emphasis Panel; NCI SUPPLEMENTARY INFORMATION: Application No. 62/357,558, filed 07/ Provocative Questions 12. Technology descriptions follow. 01/2016. Date: March 23, 2017. Inhibition of host heme oxygenase-1 Licensing Contact: James M. Time: 1:00 p.m. to 3:00 p.m. Robinson; James.Robinson4@nih.gov; Agenda: To review and evaluate grant sradovich on DSK3GMQ082PROD with NOTICES as an adjunctive treatment to improve 301–761–7542. applications. the outcome of conventional antibiotic Collaborative Research Opportunity: Place: National Cancer Institute Shady chemotherapy of Mycobacterium Grove, 9609 Medical Center Drive, Room tuberculosis (Mtb) infection. The National Institute of Allergy and 7W030, Rockville, MD 20850 (Telephone Infectious Diseases is seeking statements Conference Call). Description of Technology of capability or interest from parties Contact Person: Jennifer C. Schiltz, Ph.D., This invention describes the interested in collaborative research to Scientific Review Officer, Special Review adjunctive use of heme oxygenase-1 further evaluate HO–1 inhibitors in Branch, Division of Extramural Activities, VerDate Sep<11>2014 16:05 Feb 21, 2017 Jkt 241001 PO 00000 Frm 00029 Fmt 4703 Sfmt 4703 E:\FR\FM\22FEN1.SGM 22FEN1


Document Created: 2017-02-22 00:08:50
Document Modified: 2017-02-22 00:08:50
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
ContactLicensing information and copies of the patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301- 496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.
FR Citation82 FR 11364 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR